These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15998876)

  • 21. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemoprevention of prostate cancer - a plea].
    Schmitz-Dräger BJ; Bismarck E; Schöffski O; Fischer C
    Aktuelle Urol; 2012 May; 43(3):157-61. PubMed ID: 22639024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential for hormonal prevention trials.
    Ford LG; Brawley OW; Perlman JA; Nayfield SG; Johnson KA; Kramer BS
    Cancer; 1994 Nov; 74(9 Suppl):2726-33. PubMed ID: 7954293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ
    Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract]   [Full Text] [Related]  

  • 28. New approaches to the endocrine prevention and treatment of breast cancer.
    Howell A; Howell SJ; Evans DG
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S39-44. PubMed ID: 12819938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen for breast cancer prevention.
    Breckwoldt M; Karck U
    Exp Clin Endocrinol Diabetes; 2000; 108(4):243-6. PubMed ID: 10961352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of phase III clinical trials of prostate cancer chemoprevention.
    Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
    Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective estrogen receptor modulators and prevention of invasive breast cancer.
    Gradishar WJ; Cella D
    JAMA; 2006 Jun; 295(23):2784-6. PubMed ID: 16754726
    [No Abstract]   [Full Text] [Related]  

  • 32. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?
    Phillips KA; Lindeman GJ
    Future Oncol; 2014 Mar; 10(4):499-502. PubMed ID: 24754577
    [No Abstract]   [Full Text] [Related]  

  • 33. Chemoprevention: an important treatment option for prostate cancer.
    Calvert RC; Thompson CS; Mikhailidis DP; Morgan RJ
    J R Soc Promot Health; 2000 Sep; 120(3):146-7. PubMed ID: 11077795
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemoprevention for breast cancer.
    Bozovic-Spasojevic I; Azambuja E; McCaskill-Stevens W; Dinh P; Cardoso F
    Cancer Treat Rev; 2012 Aug; 38(5):329-39. PubMed ID: 21856081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer prevention by antihormones and other drugs: where do we stand?
    Lazzeroni M; DeCensi A
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):657-72, vii. PubMed ID: 23915737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A reconsideration of tamoxifen use for breast cancer.
    Wang PH; Chao HT
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):93-5. PubMed ID: 17638615
    [No Abstract]   [Full Text] [Related]  

  • 40. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
    Booth CM; Pater JL; Goss PE
    Cancer; 2007 May; 109(9):1927-8; author reply 1928. PubMed ID: 17354227
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.